SNDX-5613

SKU: orb1218436

Description

SNDX-5613 is a potent and specific inhibitor of Menin-MLL(Ki of 0.149 nM and a cell based IC50 of 10-20 nM). SNDX-5613 can be used for the research of MLL-rearranged (MLL-r) acute leukemias. (In Vivo):Revumenib (SNDX-5613) shows in vivo plasma IC50 of 53 nM. Revumenib treatment provides significant survival benefit and leukemic control in aggressive MOLM-13 disseminated xenografts.

Key Properties

• CAS Number: 2169919-21-3
• MW: 630.82
• Purity: >98% (HPLC)
• Formula: C₃₂H₄₇FN₆O₄S
• SMILES: O=C(C1=CC(F)=CC=C1OC2=CN=CN=C2N3CC4(C3)CCN(CC4)C[C@H]5CC[C@@H](CC5)NS(=O)(CC)=O)N(C(C)C)CC
• Target: Histone Demethylase
• Solubility: DMSO:41.67 mg/mL (66.06 mM; Need ultrasonic)

Bioactivity

• In Vivo:
  Revumenib (SNDX-5613) shows In vivo plasma IC50 of 53 nM. Revumenib treatment provides significant survival benefit and leukemic control in aggressive MOLM-13 disseminated xenografts.

Storage & Handling

• Storage: Storage temperature: -20°C. Stability: ≥ 2 years
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Quick Database Links

Gene Symbol

Histone Demethylase